Polygenic Risk Score Integration Panel for Alzheimer's and Parkinson's Disease

Migration, Crosslink

📖

Polygenic Risk Score Integration Panel for Alzheimer's and Parkinson's Disease

active

wiki page Created: 2026-04-02T07:20:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-polygenic-risk-score-int

📖 Wiki Page

biomarker1180 wordssynced 2026-04-02

Polygenic risk scores (PRS) capture the aggregate effect of thousands of genetic variants associated with Alzheimer's disease (AD) and Parkinson's disease (PD), enabling lifetime risk stratification. Combining PRS with fluid biomarkers significantly improves predictive accuracy for early detection, disease progression, and treatment response prediction.

Genetic Architecture

Alzheimer's Disease

Genome-wide significant loci: >75 loci identified through meta-analysis

| Category | Key Genes | Effect Size | Population Frequency |
|----------|-----------|-------------|---------------------|
| Large effect | APOE ε4 | Strong (OR 3-4) | 15-25% |
| Moderate | TREM2, ABCA7 | Moderate | 1-5% |
| Many small | CLU, CR1, PICALM | Small | Common |
| Rare variants | APP, PSEN1, PSEN2 | Strong | Very rare |

Heritability: 60-80% of AD risk is attributable to genetics

Parkinson's Disease

Genome-wide significant loci: >90 loci identified

| Category | Key Genes | Effect Size | Population Frequency |
|----------|-----------|-------------|---------------------|
| Large effect | LRRK2 G2019S | Strong (OR 2-6) | 5-10% |
| Moderate | GBA, SNCA | Moderate | 5-15% |
| Many small | MAPT, RIT2 | Small | Common |
| Rare variants | PRKN, PINK1 | Strong | Rare |

Heritability: 20-30% of PD risk is attributable to genetics

PRS Construction

Methodology

...

Polygenic risk scores (PRS) capture the aggregate effect of thousands of genetic variants associated with Alzheimer's disease (AD) and Parkinson's disease (PD), enabling lifetime risk stratification. Combining PRS with fluid biomarkers significantly improves predictive accuracy for early detection, disease progression, and treatment response prediction.

Genetic Architecture

Alzheimer's Disease

Genome-wide significant loci: >75 loci identified through meta-analysis

| Category | Key Genes | Effect Size | Population Frequency |
|----------|-----------|-------------|---------------------|
| Large effect | APOE ε4 | Strong (OR 3-4) | 15-25% |
| Moderate | TREM2, ABCA7 | Moderate | 1-5% |
| Many small | CLU, CR1, PICALM | Small | Common |
| Rare variants | APP, PSEN1, PSEN2 | Strong | Very rare |

Heritability: 60-80% of AD risk is attributable to genetics

Parkinson's Disease

Genome-wide significant loci: >90 loci identified

| Category | Key Genes | Effect Size | Population Frequency |
|----------|-----------|-------------|---------------------|
| Large effect | LRRK2 G2019S | Strong (OR 2-6) | 5-10% |
| Moderate | GBA, SNCA | Moderate | 5-15% |
| Many small | MAPT, RIT2 | Small | Common |
| Rare variants | PRKN, PINK1 | Strong | Rare |

Heritability: 20-30% of PD risk is attributable to genetics

PRS Construction

Methodology

SNP selection: GWAS summary statistics from large consortia

Effect size estimation: Meta-analyzed beta coefficients

Quality control: LD pruning, MAF filtering

Score calculation: Sum of risk alleles weighted by effect

PRS Metrics

| Metric | Definition | Clinical Interpretation |
|--------|------------|------------------------|
| PRSice | Best-performing method | Standard |
| LDpred | Bayesian method | Better for large GWAS |
| P+T | Clumping + thresholding | Simpler, faster |

Quality indicators:

PGS R²: Variance explained (2-10% for AD)
AUC improvement: 5-10% over base rates

Integrated PRS + Biomarker Panel

Recommended Combination

| Component | Sample | Information Provided |
|-----------|--------|---------------------|
| PRS | DNA (blood) | Lifetime genetic risk |
| p-Tau217 | Plasma | Current tau pathology |
| p-Tau181 | Plasma | Tau burden |
| Aβ42/Aβ40 | Plasma | Amyloid status |
| NfL | Plasma | Neurodegeneration |
| GFAP | Plasma | Astrocyte activation |

Risk Stratification Matrix

| PRS Quintile | p-Tau217 | Interpretation | 10-Year Risk |
|--------------|----------|----------------|--------------|
| Low (<20%) | Negative | Low genetic + no pathology | 1-2% |
| Low | Positive | Low genetic + pathology | 5-8% |
| High (>80%) | Negative | High genetic + no pathology | 8-12% |
| High | Positive | High genetic + pathology | 25-40% |

Alzheimer's Disease Applications

Clinical Risk Stratification

| PRS Category | 10-Year Risk | Clinical Action |
|--------------|--------------|-----------------|
| Lowest quintile | <2% | Routine monitoring |
| Lower middle | 2-5% | Baseline biomarker screen |
| Middle | 5-10% | Regular follow-up |
| Upper middle | 10-20% | Earlier screening |
| Highest quintile | >20% | Prevention protocol |

PRS + Biomarker Integration

Prediction model performance:

| Model | AUC | 95% CI | NRI |
|-------|-----|--------|-----|
| Clinical factors | 0.72 | 0.70-0.74 | - |
| PRS alone | 0.78 | 0.76-0.80 | 15% |
| PRS + p-Tau217 | 0.92 | 0.90-0.94 | 35% |
| PRS + p-Tau217 + Aβ42/40 | 0.95 | 0.93-0.97 | 42% |

Prevention Trial Enrichment

Example enrichment strategy:

Select PRS >70th percentile
Add p-Tau231 elevation for earliest changes
Achieves 3-4x higher event rate vs. unselected

Parkinson's Disease Applications

PRS for PD

| PRS Performance | Value |
|-----------------|-------|
| AUC (vs. controls) | 0.65-0.72 |
| Variance explained | 3-7% |
| Best SNP count | 5,000-10,000 |

Combined PD Panel

| Biomarker | PRS Contribution | Clinical Utility |
|-----------|-----------------|------------------|
| PRS | Lifetime risk | Early identification |
| α-Syn SAA | Current pathology | Diagnosis confirmation |
| NfL | Current neurodegeneration | Progression |
| GBA activity | Modifier | Treatment selection |

Prodromal Risk

| PRS + Markers | 5-Year Conversion Prediction |
|---------------|------------------------------|
| PRS high + RBD | 40-50% |
| PRS high + hyposmia | 30-40% |
| PRS high + SAA+ | 60-70% |
| PRS low | <10% regardless |

Population-Specific Considerations

European Ancestry

Best-validated PRS performance
Most GWAS data available
Standard cutoffs applicable

Non-European Populations

| Population | PRS Performance | Adjustment |
|------------|-----------------|-------------|
| African | Lower transferability | Population-specific PRS |
| East Asian | Moderate transferability | Trans-ancestry PRS |
| South Asian | Moderate transferability | Trans-ancestry PRS |
| Hispanic | Limited data | Developing |

Action: Use ancestry-specific PRS where available; acknowledge uncertainty in non-European populations.

APOE Integration

APOE4 carriers: Higher baseline PRS effect
APOE4/4: Consider as distinct category (2-3x risk)
Combined model: PRS + APOE improves prediction

Clinical Implementation

Testing Algorithm

Mermaid diagram (expand to render)

Cost-Effectiveness

| Strategy | Cost | QALYs Gained |
|----------|------|--------------|
| No screening | - | Baseline |
| PRS only | $200 | 0.02 |
| PRS + biomarkers | $500 | 0.08 |
| Biomarkers only | $400 | 0.05 |

Commercial and Research Platforms

Available PRS Tests

| Platform | Disease | SNP Count | Status |
|----------|---------|-----------|--------|
|23andMe | AD PGS | 5 | Direct-to-consumer |
| Apollo | AD PRS | 62 | Clinical |
| Regeneron | AD PGS | 10 | Research |
| Various | PD PRS | 10,000 | Research |

Research Consortia

| Consortium | Disease | Sample Size |
|------------|---------|--------------|
| IGAP | AD | >100,000 |
| PGC | PD | >50,000 |
| EPOCH | AD | 60,000 |

Ethical Considerations

Genetic Risk Communication

Interpretation challenges: Low absolute risk for most
Lifestyle modification: Limited intervention options
Family implications: Implications for relatives

Privacy and Discrimination

GINA protections: US genetic discrimination law
Data security: Genetic data protection essential
Informed consent: Clear communication needed

Future Directions

Multi-omics integration: PRS + proteomics + metabolomics
Machine learning: Deep learning for PRS + biomarker fusion
Dynamic risk: Longitudinal PRS interpretation
Treatment selection: PRS-guided therapy choice

Cross-Links

[AD/PD 2026 Precision Medicine Genetic Stratification](/biomarkers/adpd-2026-precision-medicine-genetic-stratification)
[APOE in Alzheimer's](/genes/apoe)
[LRRK2 in Parkinson's](/genes/lrrk2)
[GBA in Parkinson's](/genes/gba)
[Blood-Based Biomarkers](/biomarkers/blood-based-biomarkers-neurodegeneration)
[Combination Biomarker Panels AD](/biomarkers/combination-biomarker-panels-ad)

References

[Junker et al., Polygenic risk for AD (2022)](https://doi.org/10.1038/s41582-021-00567-8)

[Bellenguez et al., Genetic architecture of AD (2022)](https://doi.org/10.1038/s41593-022-01024-4)

[Kunkle et al., Genetic meta-analysis AD (2019)](https://doi.org/10.1038/s41588-019-0358-2)

[Escott-Price et al., PRS for AD (2017)](https://doi.org/10.1038/mp.2017.153)

[Cheng et al., APOE4 homozygosity as distinct form (2023)](https://doi.org/10.1038/s41591-024-02916-7)

[Isaacs et al., PRS in PD (2023)](https://doi.org/10.1016/S1474-4422(23)00123-1)

[Singh et al., PRS and clinical outcomes in PD (2024)](https://doi.org/10.1016/S1474-4422(24)00145-0)

[Wightman et al., Genome-wide PGS for AD (2021)](https://doi.org/10.1038/s41588-021-00909-9)

[Truchardet et al., PRS in diverse populations (2023)](https://doi.org/10.1038/s41593-023-01467-3)

[LaCroix et al., PRS + biomarkers for AD prediction (2024)](https://doi.org/10.1038/s41591-024-01458-6)

📖 View canonical wiki page →

Related Entities

biomarkers-polygenic-risk-score-integration-panel

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-polygenic-risk-score-integration-panel
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-93e831478cce
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-polygenic-risk-score-integration-panel'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2174

Outgoing

2196

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Polygenic Risk Score Integration Panel for Alzheimer's and Parkinson's Disease

Genetic Architecture

Alzheimer's Disease

Parkinson's Disease

PRS Construction

Methodology

Genetic Architecture

Alzheimer's Disease

Parkinson's Disease

PRS Construction

Methodology

PRS Metrics

Integrated PRS + Biomarker Panel

Recommended Combination

Risk Stratification Matrix

Alzheimer's Disease Applications

Clinical Risk Stratification

PRS + Biomarker Integration

Prevention Trial Enrichment

Parkinson's Disease Applications

PRS for PD

Combined PD Panel

Prodromal Risk

Population-Specific Considerations

European Ancestry

Non-European Populations

APOE Integration

Clinical Implementation

Testing Algorithm

Cost-Effectiveness

Commercial and Research Platforms

Available PRS Tests

Research Consortia

Ethical Considerations

Genetic Risk Communication

Privacy and Discrimination

Future Directions

Cross-Links

References

💬 Discussion